We are live on ! Find out more
EBAC

European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC

Delisted

EBAC was delisted on the 2nd of March, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

70.48% less ownership

Funds ownership: 70.48% → 0% (-70%)

100% less funds holding

Funds holding: 50 → 0 (-50)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $94M → $0 (-$94M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 50

Holders
–
Holders Change
-50
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
50
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
-$12.7M
2
PC
Periscope Capital
Ontario, Canada
-$7.85M
3
Millennium Management
Millennium Management
New York
-$5.99M
4
Macquarie Group
Macquarie Group
Australia
-$5.09M
5
LA
Linden Advisors
New York
-$5.03M

EBAC Hedge Fund Activity: Q1 2023 in Review

0 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q1 2023, worth a combined $0 — down 100% from $94M a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of EBAC and 0 opened new positions — a net loss of 50 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Glazer Capital LLC, exiting entirely with an estimated $12.7M sold.

  • 0 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q1 2023, down from 50 in Q4 2022.
  • Funds reported $0 of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q1 2023 and 50 closed out, a net change of -50 holders.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q1 2023 was Glazer Capital LLC, an estimated $12.7M sold.

Based on aggregated 13F filings for Q1 2023.